---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-332752"
form_type: "8-K"
ticker: "TYRA"
cik: "0001863127"
company_name: "Tyra Biosciences, Inc."
filed_at: "2026-08-04T20:04:46+00:00"
generated_at: "2026-08-04T20:06:53.198856+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tyra Biosciences Q2 net loss $45.6M; cash $353.9M; initial Ph2 data from SURF302 expected Sept 2026

## Summary
- Net loss of $45.6M in Q2 2026 vs $28.1M in Q2 2025; R&D expenses rose to $39.2M from $24.3M.
- Cash, cash equivalents and marketable securities of $353.9M as of June 30, 2026; runway into 2H 2028.
- Initial Ph2 data from SURF302 (dabogratinib in IR NMIBC) expected September 2026; n>40 enrolled.
- Initial Ph2 data from BEACH301 (achondroplasia) safety sentinel cohort including 5th dose level expected end of Q1 2027.
- Appointed Jonathan Day as EVP, Clinical Development; amended ATM sales agreement for up to $250M additional shares.

## SEC filing metadata
- accession: 0001193125-26-332752
- form_type: 8-K
- ticker: TYRA
- cik: 0001863127
- company_name: Tyra Biosciences, Inc.
- filed_at: 2026-08-04T20:04:46+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/0001193125-26-332752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1863127/000119312526332752/tyra-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-332752
- JSON: https://secwatch.observer/filing/0001193125-26-332752.json
- Plain text: https://secwatch.observer/filing/0001193125-26-332752.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.